10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON , D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended  June 30, 2009

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________

Commission file number 33-26787-D

Zynex, Inc.

(Exact name of registrant as specified in its charter)

NEVADA	90-0214497
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

8022 SOUTHPARK CIRCLE, STE 100 LITTLETON, COLORADO	80120
(Address of principal executive offices)	(Zip Code)

(303) 703-4906

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer o Accelerated filer o Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company ý

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  o  No ý

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class	Shares Outstanding as of August 6, 2009
Common Stock, par value $0.001	30,034,567

ZYNEX, INC. AND SUBSIDIARY

INDEX TO FORM 10-Q

	Page
PART I - FINANCIAL INFORMATION
Item 1.   Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2009 (unaudited) and December 31, 2008	3
Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2009 and 2008	4
Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the six months ended June 30, 2009	5
Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2009 and 2008	6
Unaudited Notes to Condensed Consolidated Financial Statements	7
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.    Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.    Controls and Procedures	24
PART II - OTHER INFORMATION
Item 1.    Legal Proceedings	25
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.    Defaults Upon Senior Securities	25
Item 6.    Exhibits	26
Signatures	27

- 2 -

PART I - FINANCIAL INFORMATION
ITEM 1.  FINANCIAL STATEMENTS
ZYNEX, INC AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
	June 30,		December 31,
	2009		2008
	(unaudited)
ASSETS
Current Assets:
Cash	$	24,553	$	-
Accounts receivable, net		6,389,218		5,614,996
Inventory		2,310,591		2,209,600
Prepaid expenses		26,960		73,324
Deferred tax asset		744,000		648,000
Other current assets		58,303		70,032
Total current assets		9,553,625		8,615,952
Property and equipment, net		2,274,403		2,096,394
Deferred financing fees, net		58,623		71,650
	$	11,886,651	$	10,783,996
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Bank overdraft	$	-	$	112,825
Current portion of notes payable and other obligations		1,861,889		1,818,059
Loans from stockholder		4,813		24,854
Accounts payable		764,136		1,037,205
Income taxes payable		1,036,644		670,000
Accrued payroll and payroll taxes		315,216		292,562
Other accrued liabilities		1,003,692		1,511,126
Total current liabilities		4,986,390		5,466,631
Derivative liability		241,463		-
Notes payable and other obligations, less current portion		99,470		115,287
Deferred tax liability		401,000		428,000
Total liabilities		5,728,323		6,009,918
Stockholders' Equity:
Preferred stock; $.001 par value, 10,000,000 shares authorized,
no shares issued or outstanding		-		-
Common stock, $.001 par value, 100,000,000 shares authorized,
30,034,567 (2009) and 29,871,041 (2008) shares issued and outstanding		30,035		29,871
Paid-in capital		3,752,271		3,676,621
Retained earnings		2,376,022		1,067,586
Total stockholders' equity		6,158,328		4,774,078
	$	11,886,651	$	10,783,996

See accompanying notes to financial statements

- 3 -

ZYNEX, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2009			2008			2009			2008
Net revenue:
Rental	$	2,599,499		$	2,100,705		$	5,249,369		$	3,892,968
Sales		1,747,089			939,755			3,329,553			1,736,212
		4,346,588			3,040,460			8,578,922			5,629,180
Cost of revenue:
Rental		386,446			113,209			621,083			216,228
Sales		390,198			165,003			638,222			518,698
		776,644			278,212			1,259,305			734,926
Gross profit		3,569,944			2,762,248			7,319,617			4,894,254
Selling, general and administrative expense		2,463,322			2,076,900			4,877,127			3,633,167
Income from operations		1,106,622			685,348			2,442,490			1,261,087
Other income (expense):
Interest income		1,744			210			2,805			1,071
Interest expense		(40,045	)		(7,722	)		(74,306	)		(23,639	)
Other income (expense)		(101	)		27,201			(1,175	)		27,201
Gain on value of derivative liability		66,402			-			196,600			-
		1,134,622			705,037			2,566,414			1,265,720
Income tax expense		426,000			416,000			907,000			746,000
Net income	$	708,622		$	289,037		$	1,659,414		$	519,720
Net income per share:
Basic	$	0.02		$	0.01		$	0.06		$	0.02
Diluted	$	0.02		$	0.01		$	0.05		$	0.02
Weighted average number of common
shares outstanding:
Basic		29,995,364			29,132,219			29,951,778			28,424,838
Diluted		30,340,987			30,277,702			30,390,143			29,976,696

See accompanying notes to financial statements

- 4 -

ZYNEX, INC AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
(UNAUDITED)
	Number		Common		Paid in			Retained			Total
	of Shares		Stock		Capital			Earnings
December 31, 2008		29,871,041	$	29,871	$	3,676,621		$	1,067,586		$	4,774,078
Cumulative effect of change
in accounting principle -
January 1, 2009
reclassification of equity-
linked financial instrument
to derivative liability		-		-		(87,085	)		(350,978	)		(438,063	)
Issuance of common stock
for option exercise		100,000		100		31,900			-			32,000
for option exercise from 2005 plan		9,500		10		2,846			-			2,856
for consulting services		54,026		54		62,896			-			62,950
Employee stock option expense		-		-		65,093			-			65,093
Net income, six months ended June 30, 2009		-		-		-			1,659,414			1,659,414
June 30, 2009		30,034,567	$	30,035	$	3,752,271		$	2,376,022		$	6,158,328

See accompanying notes to financial statements

- 5 -

ZYNEX, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
	Six Months Ended
	June 30,
	2009			2008
Cash flows from operating activities:
Net income	$	1,659,414		$	519,720
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation expense		315,698			159,655
Provision for provider discounts		25,766,923			11,049,195
Provision for losses in accounts receivable (uncollectibility)		1,556,912			755,908
Amortization of deferred consulting and financing fees		13,027			5,525
Gain on value of derivative liability		(196,600	)		-
Issuance of stock for consulting services		62,950			7,400
Provision for obsolete inventory		105,000			24,000
Gain on disposal of equipment		-			(27,201	)
Employee stock based compensation expense		65,093			35,078
Deferred tax benefit		(123,000	)		(195,000	)
Changes in operating assets and liabilities:
Accounts receivable		(28,098,057	)		(12,120,634	)
Inventory		(205,991	)		(568,758	)
Prepaid expenses		46,364			(33,394	)
Other current assets		11,729			(9,885	)
Accounts payable		(273,069	)		147,923
Accrued liabilities		(484,780	)		240,365
Income taxes payable		366,644			441,000
Net cash provided by operating activities		588,257			430,897
Cash flows from investing activities:
Proceeds from disposal of equipment		-			47,000
Purchases of equipment		(493,707	)		(546,597	)
Net cash used in investing activities		(493,707	)		(499,597	)
Cash flows from financing activities:
Decrease in bank overdraft		(112,825	)		(89,347	)
Net borrowings from line of credit		48,617			-
Payments on notes payable and capital leases		(20,604	)		(247,733	)
Repayments of loans from stockholder		(20,041	)		(28,953	)
Issuance of common stock		34,856			624,353
Net cash (used in) provided by financing activities		(69,997	)		258,320
Net increase in cash and cash
at end of period	$	24,553		$	189,620
Supplemental cash flow information:
Interest paid	$	74,306		$	6,566
Income taxes paid (including interest and penalties)	$	663,000		$	500,000

See accompanying notes to financial statements

- 6 -

ZYNEX, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

June 30, 2009

(1)         UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The condensed consolidated financial statements included herein have been prepared by Zynex, Inc. (the “Company”) pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008. Amounts as of December 31, 2008 are derived from those audited consolidated financial statements.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of June 30, 2009 and the results of operations and cash flows for the periods presented.  All such adjustments are of a normal recurring nature.  The results of operations for the three and six months ended June 30, 2009 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

As discussed and as presented in the Form 10-K for the year ended December 31, 2008, the unaudited interim financial statements as of and for the three and six months ended June 30, 2008 were restated.

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and Zynex Medical, Inc. for all of the periods presented. All intercompany balances and transactions have been eliminated in consolidation.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

The Company is operating with emphasis on cash flow and remaining compliant with covenants related to the line of credit. Management believes that its cash flow projections for 2009 are achievable and, based on billings and collections in the first half of 2009, that sufficient cash will be generated to meet the loan covenants and the Company’s financial obligations and management believes that the continued achievement of its plans will enable the Company to continue as a going concern. The Company has developed a new model for analyzing the collectability of accounts receivable. Management believes these changes have enhanced the Company’s ability to monitor collections of accounts receivable, and project cash flow more effectively. In addition, the Company has instituted various cost reductions. Management believes that, as indicated above, it has the ability to remain compliant with the terms of the line of credit. Our lender informed us in July 2009 that it has eliminated its specific healthcare lending group and transferred our account to a new loan officer. If the Company were to be in violation of its covenants in the future, it would, as it has successfully done in the past, seek to obtain amendments to the debt or waivers of the covenants so that the Company would no longer be in violation.

- 7 -

(2)           SIGNIFICANT ACCOUNTING POLICIES

USE OF ESTIMATES

Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for provider discounts and uncollectible accounts receivable and the reserve for obsolete and damaged inventory.

REVENUE RECOGNITION - ALLOWANCES FOR PROVIDER DISCOUNTS AND UNCOLLECTIBLE ACCOUNTS RECEIVABLE

The Company recognizes revenue when each of the following four conditions are met: 1) a contract or sales arrangement exists; 2) products have been shipped and title has transferred or rental services have been rendered; 3) the price of the products or services is fixed or determinable; and 4) collectibility is reasonably assured. Accordingly, the Company recognizes revenue, both rental and sales, when products have been dispensed to the patient and the patient’s having insurance has been verified. For medical products that are sold from inventories consigned at clinic locations, the Company recognizes revenue when it receives notice that the product has been prescribed and dispensed to the patient and the patient’s having insurance has been verified or for certain matters, preauthorization has been obtained from the insurance company, when required. Revenue from the rental of products is normally on a month-to-month basis and is recognized ratably over the products’ rental period. Products on rental contracts are placed in property and equipment and depreciated over their estimated useful life. All revenue is recognized at amounts estimated to be paid by customers or third party providers using the Company’s established rates, net of estimated provider discounts. The Company recognizes revenue from distributors when it ships its products fulfilling an order and title has transferred.

A significant portion of the Company’s revenues are derived, and the related receivables are due, from insurance companies or other third party payors. The nature of these receivables within this industry has typically resulted in long collection cycles. The process of determining what products will be reimbursed by third party providers and the amounts that they will reimburse is complex and depends on conditions and procedures that vary among providers and may change from time to time. The Company maintains an allowance for provider discounts and records additions to the allowance to account for the risk of nonpayment. Provider discounts result from reimbursements from insurance or other third party payors that are less than amounts claimed, where the amount claimed by the Company exceeds the insurance or other payor’s usual, customary and reasonable reimbursement rate, amounts subject to insureds’ deductibles, and when there is a benefit denial. The Company sets the amount of the allowance, and adjusts the allowance at the end of each reporting period, based on a number of factors, including historical rates of collection, trends in the historical rates of collection and current relationships and experience with insurance companies or other third party payors. If the rates of collection of past-due receivables recorded for previous fiscal periods changes, or if there is a trend in the rates of collection on those receivables, the Company may be required to change the rate at which they provide for additions to the allowance. A change in the rates of the Company’s collections can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of payors, or changes in industry rates of reimbursement. Accordingly, the provision for provider discounts recorded in the income statement as a reduction of revenue has fluctuated and may continue to fluctuate significantly from quarter to quarter.

Due to the nature of the industry and the reimbursement environment in which the Company operates, estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of third party billing arrangements and the uncertainty of reimbursement amounts for certain products or services from payors may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third party reimbursement, it is possible that management’s estimates could change in the near term, which could have an impact on results of operations and cash flows.

- 8 -

Any differences between estimated settlements and final determinations are reflected as a reduction to revenue in the period known.

In addition to the allowance for provider discounts, the Company provides an allowance for uncollectible accounts receivable. These uncollectible accounts receivable are a result of non-payment from patients who have been direct billed for co-payments or deductibles; lack of appropriate insurance coverage; and disallowances of charges by third party payors. The allowance is based on historical trends, current relationships with payors, and internal process improvements. If there were a change to a material insurance provider contract or policies or application of them by a provider, a decline in the economic condition of providers, or a significant turnover of Company personnel, the current amount of the allowance for uncollectible accounts receivable may not be adequate and may result in an increase of these levels in the future.

At June 30, 2009 and December 31, 2008, the allowance for provider discounts and uncollectible accounts are as follows:

	June 30, 2009		December 31, 2008
Allowance for provider discounts	$	24,015,744	$	12,908,123
Allowance for uncollectible accounts receivable		1,377,737		839,000
	$	25,393,481	$	13,747,123

Changes in the allowance for provider discounts and uncollectible accounts receivable for the three and six months ended June 30, 2009 and 2008 are as follows:

	Three months ended June 30,								Six months ended June 30,
	2009				2008				2009				2008
Balances, beginning		$	20,064,720			$	9,185,412			$	13,747,123			$	5,901,724
Additions debited to net sales and rental revenue			14,893,220				7,060,338				27,323,835				11,805,104
Write-offs credited to accounts receivable			(9,564,459	)			(1,948,070	)		$	(15,677,477	)			(3,409,148	)
		$	25,393,481			$	14,297,680			$	25,393,481			$	14,297,680

RECENTLY ISSUED AND ADOPTED ACCOUNTING PRONOUNCEMENTS

On January 1, 2009, the Company adopted the provisions of Emerging Issues Task Force (“EITF”) 07-05, Determining whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in paragraph 11(a) of SFAS 133.  Upon the adoption of EITF 07-05, the Company reclassified certain warrants that were previously classified equity to a derivative liability (Note 7).

In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 157, Fair Value Measurements. SFAS No. 157 establishes a framework for measuring the fair value of assets and liabilities. This framework is intended to provide increased consistency in how fair value determinations are made under various existing accounting standards which permit, or in some cases require, estimates of fair market value. SFAS No. 157 also expands financial statement disclosure requirements about a company’s use of fair value measurements, including the effect of such measures on earnings. In February 2008, the FASB issued Staff Position FAS 157-2, which delayed the effective date of SFAS 157 for nonfinancial assets and nonfinancial liabilities, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company adopted Staff Position FAS 157-2 on January 1, 2009.

- 9 -

On January 1, 2009, the Company adopted SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 establishes accounting and reporting standards for a noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. Because the Company’s subsidiary is wholly-owned by the Company, there are no noncontrolling interests, and as a result, the adoption of this standard had no effect on the Company’s consolidated financial statements.

In April 2009, the FASB issued FASB Staff Position (“FSP”) SFAS 107-1 and Accounting Principles Board (“APB”) 28-1, “Interim Disclosures about Fair Value of Financial Instruments” (“FSP 107-1”), which will require that the fair value disclosures required for all financial instruments within the scope of SFAS 107, “Disclosures about Fair Value of Financial Instruments”, be included in interim financial statements. This FSP also requires entities to disclose the method and significant assumptions used to estimate the fair value of financial instruments on an interim and annual basis and to highlight any changes from prior periods. FSP 107-1 is effective beginning with this interim period ending June 30, 2009. The adoption of FSP 107-1 did not have a material impact on the Company’s financial statements.

In June 2009, the FASB approved its Accounting Standards Codification (“Codification”) as the single source of authoritative United States accounting and reporting standards applicable for all non-governmental entities, with the exception of the SEC and its staff. The Codification which changes the referencing of financial standards is effective for interim or annual periods ending after September 15, 2009. Therefore in the third quarter of fiscal year 2009, all references made to US GAAP will use the new Codification numbering system prescribed by the FASB. As the codification is not intended to change or alter existing US GAAP, it is not expected to have any impact on the Company’s financial position or results of operations, upon adoption.

RECLASSIFICATIONS

Certain amounts in the 2008 financial statements have been reclassified to conform to the presentation used in 2009.

FAIR VALUE OF FINANCIAL INSTRUMENTS AND CREDIT RISK

The Company's financial instruments at December 31, 2008, primarily consist of accounts receivable and payable, for which current carrying amounts approximate fair value. Additionally, the carrying value of notes payable approximate fair value because interest rates on outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities. The fair value of the loans from stockholder is not practicable to estimate, due to the related party nature of the underlying transactions.

INVENTORY

Inventory is valued at the lower of cost (average) or market. Inventory consists of finished goods, consumable supplies and parts, some of which are held at different locations by health care providers or other third parties for rental or sale to patients.

The Company monitors inventory for turnover and obsolescence, and records losses for excess and obsolete inventory as appropriate. At June 30, 2009, the Company had an allowance for obsolete and damaged inventory of approximately $435,000 and an allowance of approximately $330,000 at December 31, 2008.

- 10 -

PROPERTY AND EQUIPMENT

Property and equipment as of June 30, 2009 and December 31, 2008 are as follows:

	June 30, 2009			December 31, 2008			Useful lives
Office furniture and equipment	$	329,388		$	329,389		3-7 years
Rental inventory		2,960,120			2,466,412		5 years
Vehicles		59,833			59,833		5 years
Leasehold Improvements		8,500			8,500		5 years
Assembly equipment		10,690			10,690		7 years
		3,368,531			2,874,824
Less accumulated depreciation		(1,094,128	)		(778,430	)
	$	2,274,403		$	2,096,394

(3)           EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the if-converted and treasury-stock methods. 

The calculation of basic and diluted earnings per share for the three and six months ended June 30, 2009 and 2008 is as follows:

	Three months ended June 30,					Six months ended June 30,
	2009			2008		2009			2008
Basic:
Net income applicable to common stockholders	$	708,622		$	289,037	$	1,659,414		$	519,720
Weighted average shares outstanding - basic		29,995,364			29,132,219		29,951,778			28,424,838
Net income per share - basic	$	0.02		$	0.01	$	0.06		$	0.02
Diluted:
Net income applicable to common stockholders	$	708,622		$	205,837	$	1,659,414		$	519,720
Less: Gain on value of derivative liability		(66,402	)		-		(196,600	)		-
Income available to common stockholders - diluted	$	642,220		$	205,837	$	1,462,814		$	519,720
Weighted average shares outstanding - basic		29,995,364			29,132,219		29,951,778			28,424,838
Dilutive securities		345,623			1,145,483		438,365			1,551,858
Weighted average shares outstanding - diluted		30,340,987			30,277,702		30,390,143			29,976,696
Net income per share - diluted	$	0.02		$	0.01	$	0.05		$	0.02

- 11 -

(4)         STOCK-BASED COMPENSATION PLANS

The Company has a 2005 Stock Option Plan (the "Option Plan") and has reserved 3,000,000 shares of common stock for issuance under the Option Plan. Vesting provisions are determined by the Board of Directors. All stock options under the Option Plan expire no later than ten years from the date of grant.

For the three months ended June 30, 2009 and 2008, the Company recorded compensation expense related to stock options of $33,849 and $25,185, respectively. For the six months ended June 30, 2009 and 2008, the Company recorded compensation expense related to stock options of $65,093 and $35,078, respectively. The stock compensation expense was included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations.

The Company used the following assumptions to determine the fair value of stock option grants during the six months ended June 30, 2009 and 2008:

	2009	2008
Expected term	6.25 years	6.25 years
Volatility	116.81%	112.66% to 117.67%
Risk-free interest rate	3.39%	3.09% to 3.90%
Dividend yield	0%	0%

The expected term of stock options represents the period of time that the stock options granted are expected to be outstanding based on historical exercise trends. The expected volatility is based on the historical price volatility of our common stock. The risk-free interest rate represents the U.S. Treasury bill rate for the expected term of the related stock options. The dividend yield represents our anticipated cash dividend over the expected term of the stock options.

A summary of stock option activity under the Option Plan for the six months ended June 30, 2009 is presented below:

						Weighted
				Weighted		Average
	Shares			Average		Remaining	Aggregate
	Under			Exercise		Contractual	Intrinsic
	Option			Price		Life	Value
Outstanding at January 1, 2009		732,500		$	1.17
Granted		465,000		$	1.00
Exercised		(9,500	)	$	0.30
Forfeited		(41,500	)	$	1.15
Outstanding at June 30, 2009		1,146,500		$	1.11	6.8 Years		$	148,630
Exercisable at June 30, 2009		281,500		$	1.16	4.7 Years		$	90,624

- 12 -

A summary of status of the Company’s non-vested shares as of and for the six months ended June 30, 2009 is presented below:

	Nonvested			Weighted
	Shares			Average
	Under			Grant Date
	Option			Fair Value
Non-vested at January 1, 2009		553,000		$	1.00
Granted		465,000		$	0.87
Vested		(113,000	)	$	0.88
Forfeited		(40,000	)	$	1.01
Non-vested at June 30, 2009		865,000		$	0.95

As of June 30, 2009, the Company had $565,847 of unrecognized compensation cost related to stock options that will be recognized over a weighted average period of approximately 4 years.

(5)           INCOME TAXES

The provision for income taxes is recorded at the end of each interim period based on the Company's best estimate of its effective income tax rate expected to be applicable for the full fiscal year. In the quarter ended June 30, 2009 the Company borrowed funds from the line of credit and paid outstanding 2007 income taxes and related interest and penalties.

(6)      NOTES PAYABLE

Marquette Loan

The Company has a loan agreement with Marquette Healthcare Finance (“the Lender”) that provides Zynex with a revolving credit facility of up to $3,000,000 (the “Loan”). As of June 30, 2009, the balance on the facility was $1,829,318. As of June 30, 2009, maximum borrowings available were $2,618,000 (remaining availability of $788,682).

On April 30, 2009, the Company entered into an amendment to the Loan and Security Agreement with Marquette Healthcare Finance, which covers matters stated in a prior letter agreement of April 7, 2009. In the amendment, Marquette waived Zynex’s violation of an EBITDA covenant and debt service coverage ratio covenant as of December 31, 2008 and violation of an EBITDA covenant as of March 31, 2009. Marquette did not apply any default fee or default interest rate. Marquette also waived any breach of a representation, warranty or covenant concerning the accuracy of unaudited financial statements for the first three quarters of 2008, which were restated. Marquette reserved the right to declare an event of default and any other claim with respect to the restated financial statements for these quarterly periods and any fraud or intentional misrepresentation in connection with the original financial statements for these quarterly periods. Marquette revised the minimum EBITDA covenant (on a trailing 12-month basis) as of the end of each quarterly reporting period to be as follows:

	TTM EBITDA
June 30, 2009	$1,436,000
September 30, 2009	$3,252,000
December 31, 2009	$4,111,000
Thereafter:	To be determined in Lender’s sole discretion

The amendment increased the margin to 3.25% and increased the collateral monitoring fee to $1,750 per month. The interest rate for the line of credit is the margin plus the higher of (i) a floating prime rate; or (ii) the floating LIBOR rate plus 2%.

- 13 -

The Company may borrow, repay and reborrow under the Loan. The amount available for advances under the Loan cannot exceed the lesser of the Borrowing Base, which is in general a percentage of eligible accounts receivable less a reserve and subject to a ceiling of eight trailing weeks collections, or the Facility Limit determined from time to time by the Lender. The Facility Limit is initially $3,000,000. At December 31, 2008, the Loan bore interest at a rate equal to the higher of (a) a floating prime rate plus 2.5% or (b) 4.5% (5.75% at December 31, 2008).At June 30, 2009 the loan bore interest at a rate of 6.5%. Interest is payable monthly. The Loan is secured by a first security interest in all of the Company’s assets, including accounts, contract rights, inventory, equipment and fixtures, general intangibles, intellectual property, shares of Zynex Medical, Inc. owned by the Company, and other assets. The Loan terminates, and must be paid in full, on September 23, 2011.

Fees under the Loan Agreement include an unused line fee of 0.5% per annum payable monthly on the difference between the average daily balance and the total Facility Limit. If the Company terminates the Loan Agreement prior to the termination date, there is a termination fee of 3% of the Facility Limit prior to the first anniversary of the Closing Date, 2% of the Facility Limit at any time between the first and second annual anniversary of the Closing Date and 1% at any time from the second anniversary of the Closing Date to the final termination date of the Loan. The Company also pays a collateral monitoring fee which was $1,500 per month through March 31, 2009 and was amended in April 2009 to be $1,750 per month, payable monthly in arrears on the first day of each month.

The Loan Agreement includes a number of affirmative and negative covenants on the part of the Company. Affirmative covenants concern, among other things, compliance with requirements of law, engaging only in the same businesses conducted on the Closing Date, accounting methods, financial records, notices of certain events, and financial reporting requirements. Negative covenants include a Minimum EBITDA, a Minimum Debt Service Coverage Ratio, a Minimum Current Ratio and a prohibition on dividends on shares and purchases of any Company stock. Other negative covenants include, among other things, limitations on capital expenditures in any fiscal year, operating leases, permitted indebtedness, incurrence of indebtedness, creation of liens, mergers, sales of assets or acquisitions, and transactions with affiliates.

Events of Default under the Loan Agreement include, among other things: Failure to pay any obligation under the Loan Agreement when due; failure to perform or observe covenants or other obligations under the Loan Agreement or other Loan Documents; the occurrence of a default or an event of default under any other Loan Document; a breach of any agreement relating to lockbox accounts; the occurrence of certain events related to bankruptcy or insolvency; the Company’s majority stockholder ceasing to own at least 51% of the Company’s outstanding voting capital stock; the Company’s ceasing to own 100% of the capital stock of Zynex Medical; or a Change in Control. The Company will have 15 days to cure any noticed Event of Default other than a failure to pay any of the Loan when due. Upon the occurrence of an Event of Default, the Lender may accelerate the principal of and interest on the Loan by providing notice of acceleration and the Lender’s commitment to make additional loans would terminate.

Validity Guaranty

As required by the Loan Agreement, Mr. Sandgaard has entered into a Validity Guaranty with the Lender.  Under the Validity Guaranty, Mr. Sandgaard is liable to the Lender for any loss or liability suffered by the Lender arising from any fraudulent or criminal activities of the Company or its executive officers with respect to the transactions contemplated under the Loan Documents or any fraudulent or criminal activities arising from the operation of the business of the Company, which activities are known to Mr. Sandgaard.  Mr. Sandgaard also warrants the accuracy of financial statements, the accuracy of the representations and warranties made by the Company under the Loan Agreement, and certain other matters.  He agrees to notify the Lender of a breach of any representation, warranty or covenant made by the Company.  Mr. Sandgaard’s liability under the Validity Guaranty is not to exceed the amount of the obligations owed by the Company to the Lender.  The Validity Guaranty terminates at such time that Mr. Sandgaard ceases to be the Chief Executive Officer of the Company.

- 14 -

Subordination Agreement

The Company is a party to a Subordination Agreement with Mr. Sandgaard and the Lender, pursuant to which all indebtedness of the Company owed to Mr. Sandgaard is subordinated in right of payment to all indebtedness of the Company owed to the Lender.  As part of this Agreement, Mr. Sandgaard will not demand or receive payment from the Company or exercise any remedies regarding the Subordinated Debt so long as the Senior Date remains outstanding, except that Mr. Sandgaard may receive regularly scheduled payments of principal and interest on existing promissory notes, including demand payments on the demand promissory note, so long as there is no default or Event of Default under any of the Loan Documents.  Mr. Sandgaard also subordinated any security interest held by him in the Company’s assets to the security interest of the Lender.

(7)     DERIVATIVE WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

In June 2008, the FASB ratified EITF No. 07-5, Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entity’s Own Stock. Paragraph 11(a) of SFAS No. 133 specifies that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company’s own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument. EITF 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the SFAS No. 133 paragraph 11(a) scope exception. The Company’s adoption of EITF 07-5 effective January 1, 2009, resulted in the identification of certain warrants that were determined to require liability classification because of certain provisions that may result in an adjustment to their exercise price. Accordingly, these warrants were retroactively reclassified as liabilities upon the effective date of EITF 07-5 as required by the EITF. The result was a decrease in paid in capital as of January 1, 2009, of $87,085, a decrease in retained earnings of $350,978, and the recognition of a liability of $438,063. The liability has been adjusted to fair value as of June 30, 2009, resulting in a decrease in the liability and an increase in other income of $196,600 for the six months ended June 30, 2009.

The Company uses the Black-Scholes pricing model to calculate fair value of its warrant liabilities. Key assumptions used to apply these models are as follows:

	June 30, 2009	January 1, 2009
Expected term	2.25 years	2.75 years
Volatility	116.7%	115.7%
Risk-free interest rate	3.2%	1.9%
Dividend yield	0%	0%

FAIR VALUE MEASUREMENTS

Assets and liabilities measured at fair value as of June 30, 2009, are as follows:

	Value at		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	June 30, 2009		(Level 1)		(Level 2)		(Level 3)
Warrant Liabilities	$	241,463	$	--	$	241,463	$	--

- 15 -

The fair value framework requires a categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets and liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

(8) STOCKHOLDERS' EQUITY, COMMON STOCK AND WARRANTS

In February 2009, the Company received a notice of exercise related to options for 100,000 shares of common stock; 100,000 shares of common stock were issued for cash of $32,000.

For stock warrants or options granted to non-employees, the Company measures fair value of the equity instruments utilizing the Black-Scholes method if that valuation method results in a more reliable measurement than the fair value of the consideration or the services received. For stock granted, the Company measures fair value of the shares issued utilizing the market price of the shares on the date the transaction takes place. The Company amortizes such costs over the related period of service.

(9) LITIGATION

A lawsuit was filed against the Company, its President and Chief Executive Officer and its Chief Financial Officer on April 6, 2009, in the United States District Court for the District of Colorado (Marjorie and David Mishkin v. Zynex, Inc. et al.). On April 9 and April 10, 2009, two other lawsuits were filed in the same court against the same defendants. These lawsuits allege substantially the same matters. The lawsuits refer to the April 1, 2009 announcement of the Company that it would restate its unaudited financial statements for the first three quarters of 2008. The lawsuits purport to be a class action on behalf of purchasers of the Company’s securities between May 21, 2008 and March 31, 2009. The lawsuits allege, among other things, that the defendants violated Section 10 and Rule 10b-5 of the Securities Exchange Act of 1934 by making intentionally or recklessly untrue statements of material fact and/or failing to disclose material facts regarding the financial results and operating conditions for the first three quarters of 2008. The plaintiffs ask for a determination of class action status, unspecified damages and costs of the legal action. The Company believes that the allegations are without merit and will vigorously defend itself in the lawsuit. The Company has notified its directors and officers liability insurer of the claim. At this time, the Company is not able to determine the likely outcome of the legal matters described above, nor can it estimate its potential financial exposure. Litigation is subject to inherent uncertainties, and if an unfavorable resolution of any of these matters occurs, the Company’s business, results of operations, and financial condition could be adversely affected.

(10)   SUBSEQUENT EVENTS

The Company’s management has evaluated events subsequent to June 30, 2009 through August 14, 2009 which is the issuance date of this Report.  There has been no material event noted in this period which would either impact the results reflected in this Report or the Company’s results going forward.

- 16 -

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS

The following information should be read in conjunction with the Company's condensed consolidated financial statements and related footnotes contained in this report which have been prepared assuming that we will continue as a going concern, and in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2008.

As discussed and presented in the Form 10-K for the year ended December 31, 2008, we restated the unaudited interim financial statements as of and for the three and six months ended June 30, 2008.

Results of Operations

Net Revenue.  Net revenue is comprised of net rental and sales of products and consumable supplies revenue. Net revenue for the three and six months ended June 30, 2009 was $4,346,588 and $8,578,922 an increase of $1,306,128 or 43% and $2,949,742 or 52% compared to $3,040,460 and $5,629,180 for the three and six months ended June 30, 2008 as previously restated. The increase in net revenue for the three and six months ended June 30, 2009, compared to the three and six months ended June 30, 2008 was due primarily to a greater number of products in use during the periods ended June 30, 2009. Products in use create monthly rental revenue and sales of consumable supplies for those products. The increase in the number of products in use resulted from increased prescriptions (orders) in the current as well as prior periods. The increased orders resulted from the expansion of the experienced sales force from 2007 through 2009 and greater awareness of the Company's products by end users and physicians.  

Net revenue by quarter were as follows:

	2009		2008
First quarter	$	4,232,334	$	2,588,720
Second quarter		4,346,588		3,040,460
Third quarter		-		2,198,738
Fourth quarter		-		3,935,640
Total net revenue	$	8,578,922	$	11,763,558

Our revenue is reported net, after deductions for uncollectible accounts receivable and estimated insurance company reimbursement deductions. The deductions are known throughout the health care industry as “contractual adjustments” and describe the process whereby the healthcare insurers unilaterally reduce the amount they reimburse for our products as compared to the rental rates and sales prices charged by us. The deductions from gross revenue also take into account the estimated denials of claims for our products placed with patients and other factors which may affect collectability. See “Revenue Recognition, Allowances for Provider Discounts and uncollectibile accounts receivable” in Note 2 to the Condensed Consolidated Financial Statements in this Report. These deductions, which are reflected in the allowance for provider discounts, have increased as third party payors have delayed payments and restricted amounts to be reimbursed for products provided by the Company. One significant reason is the need to adequately train billing personnel hired as a result of growth in the business.

We are introducing during the third quarter of 2009 a new product for our line of electrotherapy products. The product, called TruWave Plus, is based upon the Company’s existing hardware platform. TruWave Plus is capable of delivering three modalities of stimulation, traditional Transcutaneous Electrical Nerve Stimulation (TENS), inferential and NeuroMusculas Electrical Stimulation (NMES), within the same product. We do not know what reimbursement levels will be allowed by third party payors for sale or rental of this new product and we do not know whether coverage will be denied under any disallowance policies.

- 17 -

Net Product Rental Revenue.  Net product rental revenue for the three and six months ended June 30, 2009 was $2,599,499 and $5,249,369 an increase of $498,794 or 24% and $1,356,401 or 35% compared to $2,100,705 and $3,892,968 for the three and six months ended June 30, 2008 as previously restated. The increase in net product rental revenue for the three and six months June 30, 2009 was due primarily to a greater number of products in use during the periods ended June 30, 2009. Reasons for greater number of products in use are indicated in “Net Revenue” above.

Net product rental revenue for the three and six months ended June 30, 2009 made up 60% and 61% of net revenue compared to 69% and 69% for the three and six months ended June 30, 2008. The decrease in the percentage of total net revenue from product rental revenue during the first three months of 2009 was due primarily to increased orders for sales of products compared to orders for rentals of products and increased sales of consumable products. The increase in net supplies sales revenue for the three and six months ended June 30, 2009 was due primarily to a greater number of products in use during the periods ended June 30, 2009 generating sales of consumable supplies to users of the Company’s products

Our products may be rented on a monthly basis or purchased. Renters are primarily patients and third party insurance payors that pay on their behalf. If the patient is covered by health insurance, the third party payer typically determines whether the patient will rent or purchase a unit depending on the anticipated time period for its use. If contractually arranged, a rental continues until an amount equal to the purchase price is paid when we transfer ownership of the product to the patient and cease rental charges.

Net Sales Revenue. Net sales revenue for the three and six months ended June 30, 2009 was $1,747,089 and $3,329,553 an increase of $807,334 or 86% and $1,593,341 or 92% compared to $939,755 and $1,736,212 for the three and six months ended June 30, 2008 as previously restated. Net sales of products (not including consumable supplies) revenue for the three and six months ended June 30, 2009 was $381,816 and $808,560 an increase of $228,106 or 148% and $585,135 or 262% compared to $153,710 and $223,425 for the three and six months ended June 30, 2008. The increase in net sales revenue for such products for the three and six months ended June 30, 2009, compared to the three and six months ended March 31, 2008 was due primarily to increased orders for sales of products for the reasons indicated in “Net Revenue” above.

Net sales revenue includes sales of consumable supplies for the three and six months ended June 30, 2009 was $1,365,273 and $2,520,993 an increase of $579,227 or 74% and $1,008,205 or 67% compared to $786,046 and $1,512,788 for the three and six months ended June 30, 2008 as previously restated. The increase in net supplies sales revenue for the three and six months ended June 30, 2009 was due primarily to a greater number of products in use during the periods ended June 30, 2009 generating sales of consumable supplies to users of the Company’s products. Reasons for the greater number of products in use are indicated in “Net Revenue” above. The majority of this revenue is derived from surface electrodes sent to existing patients each month.

Net product sales revenue for the three and six months ended June 30, 2009 made up 40% and 39% of net revenue compared to 31% and 31% for the three and six months ended June 30, 2008. The increase in the percentage of total net revenue during the first six months of 2009 was due primarily to a greater number of products in use during the periods ended June 30, 2009 generating sales of consumable supplies to users of the Company’s products.

Our products may be purchased. Purchasers are primarily patients and healthcare providers; there are also purchases by dealers. If the patient is covered by health insurance, the third party payer typically determines whether the patient will rent or purchase a unit depending on the anticipated time period for its use.

Gross Profit. Gross profit for the three and six months ended June 30, 2009, was $3,569,944 and $7,319,617 or 82% and 85% of net rental and sales revenue.  

- 18 -

For the three months ended June 30, 2009, this represents an increase of $807,696 or 29% compared to $2,762,248 or 91% of net rental and sales revenue for the three months ended June 30, 2008. The increase in gross profit for the three months ended June 30, 2009 compared to the three months ended June 30, 2008 is primarily because net revenue increased. The decrease in gross profit percentage for the three months ended June 30, 2009 as compared with the same period in 2008 is primarily from increases in the estimate for insurance company reimbursement deductions which increased the allowance for provider discounts and reduced revenue.

For the six months ended June 30, 2009, this represents an increase of $2,425,363 or 50% compared to $4,894,254 or 87% of net rental and sales revenue for the six months ended June 30, 2008. The increase in gross profit for the six months ended June 30, 2009 compared to the six months ended June 30, 2008 is primarily because net revenue increased. The decrease in gross profit percentage for the six months ended June 30, 2009 as compared with the same period in 2008 is primarily from increases in the estimate for insurance company reimbursement deductions which increased the allowance for provider discounts and reduced revenue

Selling, General and Administrative Expenses.  Selling, general and administrative expenses for the three and six months ended June 30, 2009 was $2,463,322 and $4,877,127 an increase of $386,422 or 19% and $1,243,960 or 34% compared to $2,076,900 and $3,633,167 for the three and six months ended June 30, 2008 as previously restated.  Selling expenses increased primarily due to increases in sales representative commissions. Commissions are earned by sales representatives on orders received during the period. General and administrative expenses increased primarily due to increased payroll and benefits. Selling, general and administrative expenses increased 34% while net revenue increased 52% during the six months ended June 30, 2009; this difference is due in large part to the recurring revenue from net product rentals and reoccurring sales of consumable supplies where the commission expense was recorded in a prior period.

Other Income (Expense).  Interest and other income (expense) is comprised of interest income, interest expense, other income (expense) and gain on the value of a derivative liability.

Interest income for the three and six months ended June 30, 2009 was $1,744 and $2,805, compared to $210 and $1,071 for the same periods in 2008.

Interest expense for the three and six months ended June 30, 2009 was $40,045 and $74,306, compared to $7,722 and $23,639 for the same periods in 2008. The increase in interest expense resulted primarily from the Company's borrowing under the line of credit established in September 2008.

Other income or expense for the three and six months ended June 30, 2009 was other expense of $101 and $1,175, compared to other income of $27,201 and $27,201 for the same periods in 2008. The expense in 2009 was a loss on foreign exchange. The income in 2008 was a gain on an asset disposal.

The gain on value of a derivative liability of $196,600 for the six months ended June 30, 2009 reflects a reduction in the market value of certain outstanding warrants. See “Derivative Warrant Liability” in Note 7 to the Condensed Consolidated Financial Statements in this Report.

Income Tax Expense.  We reported income tax expense, which expense includes interest and penalties, in the amount of $907,000 for the six months ended June 30, 2009 compared to $746,000 of expense for the same period in 2008 as restated. This is primarily due to our having higher income before taxes of $2,566,414 for the six months ended June 30, 2009 compared to income before taxes of $1,265,720 for the same period in 2008. The six months ended June 30, 2008 showed an effective tax rate (approximately 59%) which is higher than the statutory tax rate. This was primarily due to permanent differences between book income and taxable income, as well as interest and penalties on unpaid 2007 income taxes for the year ended December 31, 2008.

- 19 -

Liquidity and Capital Resources.

The Company’s financial statements for the three and six month periods ended June 30, 2009 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's financial statements as of and for the year ended December 31, 2008 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

The Company has developed its operating plans with emphasis on cash flow and remaining compliant with covenants related to the line of credit. Management believes that its cash flow projections for 2009 are achievable and, based on billings and collections in the first half of 2009, that sufficient cash will be generated to meet the loan covenants and the Company’s financial obligations. Management believes that the successful implementation of these plans will enable the Company to continue as a going concern.

Line of Credit

Please see Note 6 of the Condensed Consolidated Financial Statements in this Report and Item 1A, Risk Factors, below for information on a line of credit established with Marquette Healthcare Finance in September 2008.  On April 30, 2009, we entered into an amendment to the Loan and Security Agreement with Marquette Healthcare Finance, which amendment covers matters stated in a prior letter agreement of April 7, 2009.  In the amendment, Marquette waived Zynex’s not meeting the EBITDA and debt service coverage ratio covenants as of December 31, 2008 and not meeting the EBITDA covenant as of March 31, 2009. Marquette did not apply any default fee or default interest rate.  Marquette also waived any breach of representation warranty or covenant concerning the accuracy of the unaudited financial statements for the first three quarters of 2008 which were restated. Marquette reserved the right to declare an event of default and any other claim with respect to the restated financial statements for these quarterly periods and any fraud or misrepresentation in connection with the original financial statements for these quarterly periods. Marquette revised the minimum EBITDA covenant (on a trailing 12 month basis) as of the end of each quarterly period to be as follows:

June 30, 2009:	$1,436,000
September 30, 2009:	$3,242,000
December 31, 2009:	$4,111,000
Thereafter:	To be determined in lender’s sole discretion

The amendment increased the margin to 3.25% and increased the collateral monitoring fee to $1,750 per month. The interest rate for the line of credit is the margin plus the higher of the (i) a floating prime rate; or (ii) the floating LIBOR rate plus 2%.

Limited Liquidity

We have limited liquidity.  Our limited liquidity is primarily a result of (a) the required high levels of inventory with sales representatives that are standard in the electrotherapy industry, (b) the payment of commissions to salespersons based on sales or rental orders prior to payments for the corresponding product by insurers, (c) the high level of outstanding accounts receivable because of the deferred payment practices of third party health payors, (d) the increasing level of delayed payments and restricted amounts for reimbursements by third party payors for the Company’s products, (e) the need for improvements to the Company’s internal billing processes and (f) delayed cost recovery inherent in rental transactions. Our growth results in higher cash needs.

- 20 -

Our long-term business plan continues to contemplate growth in revenues and thus to require, among other things, funds for the purchases of equipment, primarily for rental inventory, and the payment of commissions to an increasing number of sales representatives.

The plans of the Company’s management indicate that, while uncertain, the Company’s projected cash flows from operating activities and borrowing available under the Marquette line of credit will fund our cash requirements for the year ending December 31, 2009.  The availability of the line of credit depends our ongoing compliance with covenants, representations and warranties in the agreement for the line of credit and borrowing base limitations. Although the maximum amount of the line of credit is $3,000,000, the amount available for borrowing under the line of credit is subject to a ceiling based upon eight trailing weeks of collections and other limitations and is thus less than the maximum amount ($2,618,000 available as of June 30, 2009, remaining availability of $788,682). The balance on the line of credit at June 30, 2009 was $1,829,318. At August 12, 2009, the balance on the line was $1,499,112.

There is no assurance that our operations and available borrowings will provide enough cash for operating requirements or for the additional purchases of equipment. For this reason or to lower expenses, we may seek to reduce expenses during 2009. We have no arrangements for any additional external financing of debt or equity, and we are not certain whether any such financing would be available on acceptable terms. Any additional debt would require the approval of Marquette.

Our limited liquidity and dependence on operating cash flow means that risks involved in our business can significantly affect our liquidity. Contingencies such as unanticipated shortfalls in revenues or increases in expenses could affect our projected revenue, cash flows from operations and liquidity.

In May 2009, the Company paid approximately $660,000 of federal income taxes and related interest and penalties owed for 2007. The funds for this payment were obtained through borrowings under the Company’s line of credit.

Cash provided by operating activities was $588,257 for the six months ended June 30, 2009 compared to $430,897 of cash provided by operating activities for the six months ended June 30, 2008. The primary reasons for the increase in cash flow was a reduction in inventory purchases in 2009 compared to 2008 and larger net income in 2009.

Cash used in investing activities for the six months ended June 30, 2009 was $493,707 compared to cash used in investing activities of $499,597 for the six months ended June 30, 2008. Cash used in investing activities primarily represents the purchase and in-house production of rental products as well as some purchases of capital equipment. In 2008 this was partially offset by proceeds from the disposal of equipment.

Cash used in financing activities was $69,997 for the six months ended June 30, 2009 compared with cash provided by financing activities of $258,320 for the six months ended June 30, 2008.  The primary financing uses of cash in 2009 were repayment of the bank overdraft, notes payable and loans from a stockholder. The uses of cash in 2009 were partially offset by proceeds from the sale of common stock upon the exercise of outstanding options and advances on our line of credit. The primary financing source of cash in 2008 were from proceeds from the sales of common stock partially offset by payments on notes payable including the notes payable to a bank.   

Recently issued accounting pronouncement:

On January 1, 2009, the Company adopted the provisions of Emerging Issues Task Force (“EITF”) 07-05, Determining whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in paragraph 11(a) of SFAS 133.  Upon the adoption of EITF 07-05, the Company reclassified certain warrants that were previously classified equity to a derivative liability (Note 7).

- 21 -

In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 157, Fair Value Measurements. SFAS No. 157 establishes a framework for measuring the fair value of assets and liabilities. This framework is intended to provide increased consistency in how fair value determinations are made under various existing accounting standards which permit, or in some cases require, estimates of fair market value. SFAS No. 157 also expands financial statement disclosure requirements about a company’s use of fair value measurements, including the effect of such measures on earnings. In February 2008, the FASB issued Staff Position FAS 157-2, which delayed the effective date of SFAS 157 for nonfinancial assets and nonfinancial liabilities, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company adopted Staff Position FAS 157-2 on January 1, 2009.

On January 1, 2009, the Company adopted SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 establishes accounting and reporting standards for a noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. Because the Company’s subsidiary is wholly-owned by the Company, there are no noncontrolling interests, and as a result, the adoption of this standard had no effect on the Company’s consolidated financial statements.

In April 2009, the FASB issued FASB Staff Position (“FSP”) SFAS 107-1 and Accounting Principles Board (“APB”) 28-1, “Interim Disclosures about Fair Value of Financial Instruments” (“FSP 107-1”), which will require that the fair value disclosures required for all financial instruments within the scope of SFAS 107, “Disclosures about Fair Value of Financial Instruments”, be included in interim financial statements. This FSP also requires entities to disclose the method and significant assumptions used to estimate the fair value of financial instruments on an interim and annual basis and to highlight any changes from prior periods. FSP 107-1 is effective beginning with this interim period ending June 30, 2009. The adoption of FSP 107-1 did not have a material impact on the Company’s financial statements.

In June 2009, the FASB approved its Accounting Standards Codification (“Codification”) as the single source of authoritative United States accounting and reporting standards applicable for all non-governmental entities, with the exception of the SEC and its staff. The Codification which changes the referencing of financial standards is effective for interim or annual periods ending after September 15, 2009. Therefore in the third quarter of fiscal year 2009, all references made to US GAAP will use the new Codification numbering system prescribed by the FASB. As the codification is not intended to change or alter existing US GAAP, it is not expected to have any impact on the Company’s financial position or results of operations, upon adoption.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There are several accounting policies that involve management’s judgments and estimates and are critical to understanding our historical and future performance, as these policies and estimates affect the reported amounts of revenue and other significant areas in our reported financial statements.

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” located within our 10-K filed on April 15, 2009 for the year ended December 31, 2008, for further discussion of our “Critical Accounting Policies”.

On January 1, 2009, the Company adopted the provisions of Emerging Issues Task Force ( “EITF”) 07-05, Determining whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in paragraph 11(a) of SFAS 133. Upon the adoption of EITF 07-05, the Company reclassified certain warrants that were previously classified equity to a derivative liability. On January 1, 2009, we adopted the following additional critical accounting policy as a result of a newly-adopted accounting standard:

- 22 -

Derivative warrant liability

SFAS 133, as amended, requires all derivatives to be recorded on the balance sheet at fair value. As a result, beginning January 1, 2009, certain derivative warrant liabilities are now separately valued and accounted for on our balance sheet, with any changes in fair value recorded in earnings.

We utilize the Black-Scholes option-pricing model to estimate fair value. Key assumptions of the Black-Scholes option-pricing model include the market price of the Company’s stock, applicable volatility rates, risk-free interest rates and the instrument’s remaining term. These assumptions require significant management judgment. In addition, changes in any of these variables during a period can result in material changes in the fair value (and resultant gains or losses) of this derivative instrument.

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included in this quarterly report contains statements that are forward-looking, such as statements relating to plans for future expansion and other business development activities, as well as other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the need for additional capital in order to grow our business, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers for reimbursement, acceptance of our products by hospitals and clinicians, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described below and in our 10-K Report for the year ended December 31, 2008.

- 23 -

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of June 30, 2009.  Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, because of the material weaknesses in internal control over financial reporting described below, the Company’s disclosure controls and procedures were not effective as of June 30, 2009.

Based on an evaluation as of December 31, 2008, management had concluded that our internal control over financial reporting was not effective as of December 31, 2008. Our principal Chief Executive Officer and Chief Financial Officer concluded that the Company had a material weakness in its ability to produce financial statements free from material misstatements. Management reported a material weakness resulting from the combination of the following significant deficiencies:

·   The Company did not have effective controls to ensure timely write-off of uncollectible accounts receivable, resulting in an overstatement of our accounts receivable and net revenue. The controls that were not considered effective included a performance issue with the Company’s billing system which prevented timely determination of accounts to be written-off and lack of procedures to write-off uncollectible accounts receivable based upon their aging.

·   The Company was utilizing a method for calculating the allowance for provider discounts and uncollectibility that was dependent on annual calculations and annual historical results which was not reactive to rapid changes during the year. Further, this methodology was dependent upon write-offs which were not done timely.

·   The Company did not have an adequate process in place to update the inventory pricing to reflect the pricing differences between purchased items and items manufactured by the Company.

Changes in Internal Control Over Financial Reporting

In order to remediate the material weakness described above, our management implemented the following changes to our internal control over financial reporting during the first quarter of 2009:

-   We have made enhancements to the performance of our billing system to allow accounts to be analyzed timely, allowing write-offs to be made timely;

-  We have implemented procedures to write-off accounts receivable which are deemed uncollectible based upon their aging;

-   We have developed a new model for analyzing the collectability of our accounts receivable that is updated on a timely basis throughout the year. The simultaneous use of the old model and timely write-offs of uncollectible accounts receivable serves as a comparative tool to validate annual trends;

-   We have updated our inventory pricing to reflect the pricing of purchased items and items manufactured by the Company.

We expect that if the steps that we are implementing are effective throughout a period of time, such material weakness described above will be remediated. We do not believe that the costs of remediation for the above material weaknesses will have a material effect on our financial position, cash flow, or results of operations.

There was no change in our internal control over financial reporting during the quarter ended June 30, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 24 -

PART II.  OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

A lawsuit was filed against the Company, its President and Chief Executive Officer and its Chief Financial Officer on April 6, 2009, in the United States District Court for the District of Colorado (Marjorie and David Mishkin v. Zynex, Inc. et al.).  On April 9, 2009, a lawsuit was filed by Robert Hanratty in the same court against the same defendants.  On April 10, 2009, a lawsuit was filed by Denise Manandik in the same court against the same defendants.  These lawsuits allege substantially the same matters.  The lawsuits refer to the April 1, 2009 announcement of the Company that it will restate its unaudited financial statements for the first three quarters of 2008.  The lawsuits purport to be a class action on behalf of purchasers of the Company securities between May 21, 2008 and March 31, 2009.  The lawsuits allege, among other things, that the defendants violated Section 10 and Rule 10b-5 of the Securities Exchange Act of 1934 by making intentionally or recklessly untrue statements of material fact and/or failing to disclose material facts regarding the financial results and operating conditions for the first three quarters of 2008.  The plaintiffs ask for a determination of class action status, unspecified damages and costs of the legal action.  The Company believes that the allegations are without merit and will vigorously defend itself in the lawsuits.  The Company has notified its directors and officers liability insurer of the claims. 

ITEM 1A. RISK FACTORS.

The following is a revised risk factor concerning our business:

WE HAVE LIMITED LIQUIDITY BECAUSE OUR CASH REQUIREMENTS INCREASE AS OUR OPERATIONS EXPAND

Our limited liquidity is primarily a result of (a) the required high levels of inventory with sales representatives that are standard in the electrotherapy industry, (b) the payment of commissions to salespersons based on sales or rentals prior to payments for the corresponding product by insurers and whether or not there is a denial of any payment by an insurer, (c) the high level of outstanding accounts receivable because of deferred payment practices of third party health payers, (d) the increasing level of delayed payments and restricted amounts of reimbursements of third party payors for the Company’s products, (e) the need for improvements to the Company’s internal billing processes, and (f) the delayed cost recovery inherent in rental transactions.

Our liquidity depends in part on a line of credit with Marquette Healthcare Finance. This lender indicated to us in July, 2009 that it has eliminated its specific healthcare lending group and transferred our account to a new loan officer. As a result we believe the lender may be less likely to grant waivers to us in the future if we are in violation of any covenants under our line of credit. We do not know whether or on what terms the line of credit could be replaced or refinanced with another credit facility if it became necessary to do so.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

Not applicable.

- 25 -

ITEM 5. OTHER INFORMATION.

Not applicable.

ITEM 6.   EXHIBITS

(a) Exhibits

10.1	Amendment No. 2 to Loan and Security Agreement effective April 8, 2009, between Marquette Healthcare Finance and the Company, incorporated by reference to Exhibit 10 of the Company’s Current Report on Form 8-K filed with the Commission on May 6, 2009.
10.2	Amendment to Employment Agreement among the Company, Zynex Medical, Inc., and Thomas Sandgaard dated as of July 1, 2009.
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350

- 26 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ZYNEX, INC.
Dated August 14, 2009	/s/ Thomas Sandgaard
	Thomas Sandgaard
	President, Chief Executive Officer and Treasurer

Dated August 14, 2009	/s/ Fritz G. Allison
	Fritz G. Allison
	Chief Financial Officer

- 27 -

EX-10.2

Exhibit 10.2

AMENDMENT TO EMPLOYMENT AGREEMENT

  This Amendment (“Amendment”) is made among Zynex Medical, Inc., a Colorado corporation and Zynex, Inc., a Nevada corporation (collectively, “Employer”), and Thomas Sandgaard (the “Employee”), to amend certain provisions of the Employment Agreement (the “Agreement”), dated February 1, 2004, between Employee and Zynex Medical, Inc., as such Agreement was amended by the amendment dated January 1, 2005.

1.           The Agreement is hereby amended to add Zynex, Inc. as a party.  All references to “Employer” contained in the Agreement shall refer to Zynex Medical, Inc. and Zynex, Inc. collectively.

2. Section (1) of the Agreement is hereby amended and restated in its entirety as follows:

1. Term.  Subject to the terms of this Section 1 and Sections 7, 8 and 9, this Agreement shall commence on February 1, 2004 and expire on the earlier of the Employee’s death, resignation, or December 31, 2009 (the date on which this Agreement shall expire, as such date may be extended in accordance with the terms of this Section 1 is hereinafter referred to as the "Expiration Date").  Subject to the terms of Sections 7, 8 and 9, unless either party gives written notice to the other of its desire to terminate this Agreement at least thirty days prior to the then current Expiration Date or Extended Period (the "Termination Notification Date"), this Agreement will be automatically extended for further period(s) of one year from the then current Expiration Date (the "Extended Period") on the same terms and conditions as herein set forth.  Except when the contrary is indicated, the phrase "the term of this Agreement" shall henceforth be deemed to include the Extended Period.

3.           Section (4) of the Agreement is hereby amended and restated in its entirety as follows:

4.  Compensation.

a.           Commencing July 1, 2009, the Employer shall pay to the Employee for the loyal and consistent services provided to it hereunder a fee at the rate of $24,000 per month.  The Employee’s compensation shall be reviewed at least annually for appropriate adjustments at the end of each year as determined by the Board of Directors of Zynex, Inc. (the “Board”).

b.           Employee shall also receive after the end of each quarter during the term of this Agreement, bonus compensation based on exceeding cash collections and EBITDA amounts as shown in the budget of Zynex, Inc. that has been accepted by the Board for the applicable period as follows:

Cash Collections Meeting Budgeted Amounts for Quarter	Bonus
Less than 100%	$0
at or >100%	$20,000
EBITDA Meeting Budgeted Amounts for Quarter	Bonus
Less than 100%	$0
at or >100%	$20,000

c.           The Board may include or exclude amounts from cash collections or EBITDA for purposes of calculating the bonus if the Board deems such amounts to be unusual or infrequent.

d.           If the Employee has been disabled for a period of at least three months during which period he was disabled for 30 consecutive days, the Employer may elect, upon notice to the Employee, to pay the Employee one-third of the base compensation the Employee would otherwise be entitled to pursuant to Section 4(a) for the relevant quarter and shall thereupon have no further compensation obligations under this Section 4 or under any provisions for reimbursement of expenses.  Disability shall mean the Employee's inability, due to sickness or injury, to perform effectively his duties hereunder.

e.           If Employee is terminated or the Employer notifies the Employee in respect of his disability, incentive compensation in respect of the fiscal quarter of such termination or in which such notice is given shall be paid an amount equal to the product of the incentive compensation to which he would otherwise be entitled, multiplied by a fraction having a numerator equal to the number of days in such quarter preceding the date of termination and a denominator equal to 90; provided that the Employee shall not be entitled to any unpaid incentive compensation amounts if Employee is terminated pursuant to Section 6 below.

4.           The paragraph below is hereby added as new Section 10 and the existing Section 10 and subsequent Sections are hereby re-numbered accordingly:

10.         Inventions.  The Employee hereby sells, transfers and assigns to the Employer or to any person, or entity designated by the Employer, all of the entire right, title and interest of the Employee in and to all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived by the Employee, solely or jointly, or in whole or in part, during or before the term hereof which (i) relate to methods, apparatus, designs, products, processes or devices sold, leased, used or under construction or development by the Employer or any subsidiary or (ii) otherwise relate to or pertain to the business, functions or operations of the Employer or any subsidiary.  The Employee shall communicate promptly and disclose to the Employer, in such form as the Employer requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements; and, whether during the term hereof or thereafter, the Employee shall execute and deliver to the Employer such formal transfers and assignments and such other papers and documents as may be required of the Employee to permit the Employer or any person or entity designated by the Employer to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereon.  Any invention by the Employee within one year following the termination of this Agreement shall be deemed to fall within the provisions of this paragraph unless proved by the Employee to have been first conceived and made following such termination.

Except as expressly modified by this Amendment, all other terms and conditions of the Agreement shall remain in full force and effect and shall not be altered by this Amendment.

The undersigned have executed this Amendment effective as of July 1, 2009.

Zynex, Inc.

  /s/ Thomas Sandgaard

By:  Thomas Sandgaard

Its:  CEO

Zynex Medical, Inc.

  /s/ Thomas Sandgaard

By:  Thomas Sandgaard

Its:  CEO

Thomas Sandgaard

  /s/ Thomas Sandgaard

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Thomas Sandgaard, certify that:

1.           I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2009 of Zynex, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:  August 14, 2009

/s/  THOMAS SANDGAARD

Thomas Sandgaard

President and Chief Executive Officer

Principal Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Fritz G. Allison, certify that:

1.           I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2009 of Zynex, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:  August 14, 2009

/s/  FRITZ G. ALLISON

Fritz G. Allison

Chief Financial Officer

Principal Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF 10-Q REPORT OF

ZYNEX, INC.

FOR THE QUARTER ENDED JUNE 30, 2009

Each of the undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his knowledge:

1.   This 10-Q Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.   The information contained in such 10-Q Report fairly presents, in all material respects, the financial condition and results of operations of Zynex.

This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the 10-Q Report. A signed original of this statement has been provided to Zynex and will be retained by Zynex and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification is executed as of  Dated:  August 14, 2009.

/s/ Thomas Sandgaard                                                                

Thomas Sandgaard

President and Chief Executive Officer

/s/ Fritz G. Allison                                                      

Fritz G. Allison

Chief Financial Officer